Precipio (NASDAQ:PRPO) Stock Price Passes Below 200 Day Moving Average – Should You Sell?

Precipio, Inc. (NASDAQ:PRPO)’s share price passed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $25.12 and traded as low as $20.20. Precipio shares last traded at $21.65, with a volume of 21,130 shares.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the stock. Wall Street Zen cut shares of Precipio from a “buy” rating to a “hold” rating in a research report on Saturday, May 16th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Precipio in a report on Friday, July 17th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company presently has an average rating of “Sell”.

Precipio Stock Up 2.2%

The firm’s 50-day moving average price is $23.48 and its 200-day moving average price is $25.12. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.56 and a quick ratio of 1.33. The company has a market cap of $38.75 million, a price-to-earnings ratio of -46.06 and a beta of 1.27.

Precipio (NASDAQ:PRPO) last posted its earnings results on Thursday, May 14th. The biotechnology company reported ($0.81) earnings per share for the quarter. Precipio had a negative net margin of 3.57% and a negative return on equity of 6.73%. The business had revenue of $6.71 million for the quarter.

Institutional Investors Weigh In On Precipio

Several institutional investors and hedge funds have recently modified their holdings of the stock. Renaissance Technologies LLC raised its holdings in shares of Precipio by 33.1% during the 1st quarter. Renaissance Technologies LLC now owns 19,300 shares of the biotechnology company’s stock valued at $482,000 after buying an additional 4,800 shares during the period. Geode Capital Management LLC grew its position in Precipio by 5.1% in the fourth quarter. Geode Capital Management LLC now owns 16,388 shares of the biotechnology company’s stock valued at $377,000 after acquiring an additional 789 shares in the last quarter. Finally, Susquehanna International Group LLP purchased a new stake in shares of Precipio during the third quarter valued at approximately $194,000. Hedge funds and other institutional investors own 10.45% of the company’s stock.

About Precipio

Precipio, Inc is a clinical-stage diagnostics and medical technology company focused on advancing the detection and management of hematologic diseases. The firm develops precision diagnostic solutions that integrate digital morphology, immunophenotyping, and molecular testing to improve the diagnosis of leukemia and related blood disorders. Precipio’s approach is designed to enhance the accuracy and speed of laboratory workflows, helping physicians tailor treatment strategies more effectively.

The company’s core offerings include an automated digital imaging and analysis platform that captures and classifies blood and bone marrow cell images at high throughput.